<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01014052</url>
  </required_header>
  <id_info>
    <org_study_id>RET IRD 01</org_study_id>
    <nct_id>NCT01014052</nct_id>
  </id_info>
  <brief_title>Safety/Proof of Concept Study of Oral QLT091001 in Subjects With Leber Congenital Amaurosis (LCA) or Retinitis Pigmentosa (RP) Due to Retinal Pigment Epithelial 65 Protein (RPE65) or Lecithin:Retinol Acyltransferase (LRAT) Mutations</brief_title>
  <official_title>Phase 1b Study to Evaluate QLT091001 in Subjects With Leber Congenital Amaurosis (LCA) or Retinitis Pigmentosa (RP) Due to Inherited Deficiencies of Retinal Pigment Epithelial 65 Protein (RPE65) or Lecithin:Retinol Acyltransferase (LRAT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>QLT Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>QLT Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is:

        -  to evaluate the safety of oral QLT091001

        -  to evaluate whether 7-day treatment with oral QLT091001 can improve visual function in
           subjects with LCA or RP due to RPE65 or LRAT mutations

        -  to evaluate duration of visual function improvement (if observed)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Field</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vital signs, clinical laboratory tests, electrocardiogram (ECG), and adverse events</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">32</enrollment>
  <condition>LCA (Leber Congenital Amaurosis)</condition>
  <condition>RP (Retinitis Pigmentosa)</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>QLT091001</intervention_name>
    <description>oral QLT091001 administered once daily for 7 days</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects diagnosed with LCA or RP (with a mutation in either RPE65 or LRAT)

               -  Subjects with LCA must be 5-65 years of age

               -  Subjects with RP must be 18-65 years of age

          -  Subjects who have a &quot;best-corrected&quot; visual acuity of 3 letters or better (20/800
             Snellen equivalent) or viable photoreceptors on OCT/FAF.

        Exclusion Criteria:

          -  Subjects who are actively participating in an experimental therapy study or who have
             received experimental therapy within 60 days of Day 0.

          -  Subjects with any clinically important abnormal physical finding at Screening.

          -  Subjects who have taken any prescription or investigational oral retinoid medication
             (e.g., Accutane,® Soriatane®) within 6 months of Day 0 and subjects who did not
             tolerate their previous oral retinoid medication will be excluded regardless of the
             time of last exposure.

          -  Subjects with a history of diabetes or chronic hyperlipidemia, hepatitis,
             pancreatitis, or cirrhosis.

          -  Subjects who have taken any supplements containing ≥10,000 IU vitamin A within 60 days
             of screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sushanta Mallick</last_name>
    <role>Study Director</role>
    <affiliation>QLT Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Chicago Lighthouse for People Who Are Blind or Visually Impaired (The Pangere Center For Inherited Retinal Diseases)</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wilmer Eye Institute (Johns Hopkins University)</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scheie Eye Institute</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal Children's Hospital, McGill University Health Centre</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3H 1P3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for Ophthalmic Research, University of Tubingen</name>
      <address>
        <city>Tubingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Rotterdam Eye Hospital</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moorefield Eye Hospital</name>
      <address>
        <city>London</city>
        <zip>EC1 V2PD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 12, 2009</study_first_submitted>
  <study_first_submitted_qc>November 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2009</study_first_posted>
  <last_update_submitted>May 13, 2013</last_update_submitted>
  <last_update_submitted_qc>May 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 14, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinitis</mesh_term>
    <mesh_term>Retinitis Pigmentosa</mesh_term>
    <mesh_term>Cone-Rod Dystrophies</mesh_term>
    <mesh_term>Blindness</mesh_term>
    <mesh_term>Leber Congenital Amaurosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin A</mesh_term>
    <mesh_term>Retinol acetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

